Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE) July 21, 2023 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been discontinued due to futility based on a planned...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials